Chronic Kidney Disease

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

Four-year results from SOUL at ACC.25 were the first to test the cardiovascular benefits of an oral GLP-1 RA in high-risk type 2 diabetes.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Patients with CKD undergoing radical prostatectomy for prostate cancer experienced greater rates of adverse in-hospital outcomes.

Retransplantation in elderly patients was associated with a higher risk of DWFG but similar death-censored outcomes to primary transplantation.

The Kidney Transplant Fast Track evaluation approach was associated with a higher likelihood of waitlisting and fewer disparities by race or ethnicity.

Psychosocial interventions reduced depressive symptoms in CKD but did not have a significant impact on patients’ quality of life.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

Kidney transplant recipients who received a GLP-1 RA had a 49% lower incidence of death-censored graft loss and 31% lower mortality.

The FDA approved the sNDA for furosemide (Furoscix) to expand the indication to include treatment of edema in patients with CKD.

In part 2 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss strategies to address the CKD crisis.

In part 1 of this episode of Crisis Point, 3 nephrology experts and a patient advocate discuss CKD’s emergence as a public health crisis.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

The guidance is intended to inform the transition to outpatient care for patients with AKI-D and help care teams identify early signs of recovery.

Survey findings highlight pediatric nephrologists’ reluctance to list patients with kidney failure due to C3G or IC-MPGN for kidney transplantation.

From 1990-2021, the ASIR, ASMR, and age-standardized DALY rate of chronic kidney disease increased.

Female dialysis patients had a greater risk of infection- and withdrawal-related mortality, while men were more likely to die from cardiovascular disease and cancer.

Greater levels of RC were linked to increased CKD risk and progression to ESRD in patients with type 2 diabetes-related kidney disease.

Findings highlight the need for early frailty screening in dialysis patients and the implementation of appropriate interventions to improve outcomes.

Data from the phase 1 trial are intended to support dosing in a planned phase 2 trial in kidney transplant recipients.

Completion of the trial was announced in a financial update from Novo Nordisk, who explained the trial missed its primary endpoint for uACR improvement.

Findings call attention to age-related neurodevelopmental differences between pediatric patients with CKD and healthy controls.